News from Zentiva
Madrid, December 16, 2022. Zentiva, a Pan-European manufacturer of high-quality and affordable medicines, specialized in the marketing of prescription drugs, brands and generics, has formalized an agreement for the acquisition of several products from the pharmaceutical company Tillomed Spain, a subsidiary of the Emcure group.
This is an important transfer of up to 16 products that will be distributed and marketed by Zentiva from January 2023, at the same time that the procedures with the Spanish Medicines Agency for the corresponding transfers of the Marketing Authorization will be initiated beginning 2023. Through this acquisition, Zentiva will significantly increase its position in the Hospital sector and more specifically in the Oncology area with some value-added products complementing the products recently launched. This will increase the accessibility of state-of-the-art therapies for patients in Oncology.
Ramon Vila, General Manager Zentiva Spain: “Acquisitions like the one with Tillomed are strengthening Zentiva’s offering of affordable medicines to the people who depend on. I am proud that as a company we will continue to complement our portfolio over the next few months and years and contribute to a sustainable healthcare in Spain.”
Zentiva is a producer of high-quality affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 4,800 people and a network of production sites - including Prague, Bucharest, and Ankleshwar - Zentiva strives to be the champion of branded and generic medicines in Europe to better support people’s daily healthcare needs. We believe that people need better access to high-quality affordable medicines and healthcare more than ever. We work together with healthcare professionals, pharmacies and authorities responsible for healthcare systems on finding solutions in the area of reducing costs and improving access to healthcare. Zentiva entered into Spain in 2021 fulfilling its mission for the value of the Spanish people. More information can be found at www.zentiva.es
Tillomed is a European Pharmaceutical company with headquarters in the UK and subsidiaries in many EU countries.
Tillomed specializes in the licensing and marketing of pharmaceuticals and is focused on growth through product launches and EU expansion. Our ambition is to grow our commercial presence in Europe and to accelerate our expansion through sustainable partnerships. We strive to offer new medicines that meet genuine needs and deliver effective, high-quality, sustainable healthcare.
Tillomed is owned by Emcure, a privately held company with a strong track record of launching high quality, innovative medicines. Emcure is one of India's leading pharmaceutical companies with 11,000 employees in over 70 countries.